MDM2 and cancer: By studying mutations in the TP53 germline associated with cancer syndromes, it was discovered that MDM2 and AKT1 were potential regulators of TP53 because these proteins showed reduced interactions with the mutant p53 and there was a reduction in p53 degradation.